Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PolyPid’s D-PLEX100 May Have Way Forward Despite Phase III Miss

Executive Summary

The SHIELD I trial, for preventing surgical site infections, did not meet its primary and key secondary endpoints, but a subgroup analysis did, while COVID-19 may have muddled results.

You may also be interested in...



Deal Watch: Gemini Goes Through Second Re-Invention Via Reverse Merger With Disc Medicine

Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.

AstraZeneca Pulls Plug On Ionis’ PCSK9 Candidate

While the Phase IIb SOLANO trial of ION449 met its primary endpoint, AstraZeneca had set a high bar of 70% LDL cholesterol reduction for competitiveness that the study did not hit.

Monkeypox Is A Different Drug Development Ballgame From COVID-19

SIGA CEO Dennis Hruby spoke with Scrip about how the company is developing its drug, Tpoxx, to address the monkeypox outbreak.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel